GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (OTCPK:SHPHF) » Definitions » PEG Ratio

Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) PEG Ratio : N/A (As of Jun. 18, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Sihuan Pharmaceutical Holdings Group's PE Ratio without NRI is 0.00. Sihuan Pharmaceutical Holdings Group's 5-Year EBITDA growth rate is 0.00%. Therefore, Sihuan Pharmaceutical Holdings Group's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Sihuan Pharmaceutical Holdings Group's PEG Ratio or its related term are showing as below:


During the past 13 years, Sihuan Pharmaceutical Holdings Group's highest PEG Ratio was 7.35. The lowest was 0.27. And the median was 0.74.


SHPHF's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.68
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Sihuan Pharmaceutical Holdings Group PEG Ratio Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group PEG Ratio Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sihuan Pharmaceutical Holdings Group's PEG Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sihuan Pharmaceutical Holdings Group's PEG Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's PEG Ratio falls into.



Sihuan Pharmaceutical Holdings Group PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Sihuan Pharmaceutical Holdings Group's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Sihuan Pharmaceutical Holdings Group  (OTCPK:SHPHF) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Sihuan Pharmaceutical Holdings Group PEG Ratio Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical Holdings Group) Business Description

Traded in Other Exchanges
Address
Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.